Genomics in personalized cancer medicine and its impact on earlydrug development in China: report from the 6th Annual Meeting of the US Chinese Anti-Cancer Association(USCACA) at the 50th ASCOAnnual Meeting  

作　　者：Wei Zhang Shi-Yuan Cheng Li-Fang Hou Li Yan Yun-Guang Tong 

机构地区：[1]Executive Committee of the US Chinese Anti-Cancer Association (USCACA) [2]Department of Pediatrics,University of Illinois at Chicago [3]Deparment of Neurology,Northwestern University Feinberg School of Medicine [4]Deparment of Preventive Medicine,Northwestern University Feinberg School of Medicine [5]School of Oncology,Peking University [6]Department of Medicine,Cedars-Sinai Medical Center,UCLA School of Medicine

出　　处：《Chinese Journal of Cancer》2014年第8期371-375,共5页

摘　　要：The 6th Annual Meeting of the United States Chinese Anti-Cancer Association(USCACA) was held in conjunction with the 50 th Annual Meeting of American Society of Clinical Oncology(ASCO) on May 30, 2014 in Chicago, Illinois, the United States of America. With a focus on personalized medicine, the conference featured novel approaches to investigate genomic aberrations in cancer cells and innovative clinical trial designs to expedite cancer drug development in biomarker-defined patient populations. A panel discussion further provided in-depth advice on advancing development of personalized cancer medicines in China. The conference also summarized USCACA key initiatives and accomplishments, including two awards designated to recognize young investigators from China for their achievements and to support their training in the United States. As an effort to promote international collaboration, USCACA will team up with Chinese Society of Clinical Oncology(CSCO) to host a joint session on "Breakthrough Cancer Medicines" at the upcoming CSCO Annual Meeting on September 20 th, 2014 in Xiamen, China.The 6th Annual Meeting of the United States Chinese Anti-Cancer Association （USCACA） was held in conjunction with the 50th Annual Meeting of American Society of Clinical Oncology （ASCO） on May 30, 2014 in Chicago, Illinois, the United States of America. With a focus on personalized medicine, the conference featured novel approaches to investigate genomic aberrations in cancer cells and innovative clinical trial designs to expedite cancer drug development in biomarker-defined patient populations. A panel discussion further provided in-depth advice on advancing development of personalized cancer medicines in China. The conference also summarized USCACA key initiatives and accomplishments, including two awards designated to recognize young investigators from China for their achievements and to support their training in the United States. As an effort to promote international collaboration, USCACA will team up with Chinese Society of Clinical Oncology （CSCO） to host a joint session on ＂Breakthrough Cancer Medicines＂ at the upcoming CSCO Annual Meeting on September 20th, 2014 in Xiamen, China.

关 键 词：医学基因组学 药物开发 抗癌药物 个性化 中国 美国 年会 临床 

分 类 号：R-2[医药卫生]